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ncidence, Predictors, Management,
mmediate and Long-Term Outcomes
ollowing Grade III Coronary Perforation
asha Al-Lamee, MA,*†‡ Alfonso Ielasi, MD,* Azeem Latib, MD,*†
osmo Godino, MD,*† Massimo Ferraro,† Marco Mussardo, MD,* Francesco Arioli, MD,*
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bjectives The aim of this study was to evaluate the incidence, predictors, management, and clinical
utcomes in patients with grade III coronary perforation during percutaneous coronary intervention.
ackground Grade III coronary perforation is a rare but recognized complication associated with
igh morbidity and mortality.
ethods From 24,465 patients undergoing percutaneous coronary intervention from May 1993 to
ecember 2009, 56 patients had grade III coronary perforation.
esults Most lesions were complex: 44.6% type B2, 51.8% type C, and 28.6% chronic total occlusions,
nd within a small vessel (2.5 mm) in 32.1%. Glycoprotein IIb/IIIa inhibitors were administered in 17.9%
f patients. The device causing perforation was intracoronary balloon in 50%: 53.6% compliant, 46.4%
oncompliant; intracoronary guidewire in 17.9%; rotablation in 3.6%; and directional atherectomy in
.6%. Following perforation, immediate treatment and success rates, respectively, were prolonged bal-
oon inﬂation 58.9%, 54.5%; covered stent implantation 46.4%, 84.6%; coronary artery bypass graft sur-
ery (CABG) and surgical repair 16.0%, 44.4%; and coil embolization 1.8%, 100%. Multiple methods were
equired in 39.3%. During the procedure (n  56), 19.6% required cardiopulmonary resuscitation and
.6% died. In-hospital (n  54), 3.7% required CABG, 14.8% died. The combined procedural and in-
ospital myocardial infarction rate was 42.9%, and major adverse cardiac event rate was 55.4%. At clini-
al follow-up (n  46) (median: 38.1 months, range 7.6 to 122.8), 4.3% had a myocardial infarction, 4.3%
equired CABG, and 15.2% died. The target lesion revascularization rate was 13%, with target vessel re-
ascularization in 19.6%, and major adverse cardiac events in 41.3%.
onclusions Grade III coronary perforation is associated with complex lesions and high acute and long-
erm major adverse cardiac event rates. (J Am Coll Cardiol Intv 2011;4:87–95) © 2011 by the American
ollege of Cardiology Foundation
rom the *Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy; †Interventional Cardiology Unit,
MO-GVM Centro Cuore Columbus, Milan, Italy; and the ‡Imperial College Healthcare National Health Service Trust,
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Grade III Coronary Perforation During PCI
88rade III coronary perforation or coronary rupture is an
xtremely rare but well recognized complication of percutane-
us coronary intervention (PCI) (1,2). It is defined by the Ellis
riteria as a perforation resulting in extravasation of blood
hrough a frank perforation (1 mm) or spilling into an
natomic cavity (3). Previous studies reporting the incidence,
redictors, and management of coronary perforation have
ncompassed all 3 grades of coronary perforation, but there
ave been no studies specifically focusing on these aspects in
he grade III subgroup alone. The incidence of grades I to III
oronary perforation ranges from 0.1% to 3.0% (1,3–6).
See page 96
tudies have reported predictors of coronary perforation as:
emale sex (2,3), calcified and noncompliant arteries (7,8),
type C coronary lesions, previous
coronary artery bypass grafting
(CABG), the use of atheroabla-
tive devices (2), older patient
groups, hypertension and non–
ST-segment elevation myocar-
dial infarction (9).
Grade III coronary perfora-
tion is the most serious form of
perforation and is associated
with the highest mortality rates
ranging from 7% to 44% of
cases (9 –12). It is also associ-
ated with very high rates of
cardiac tamponade of up to
40% (10) and the need for
emergency CABG in 20% to
40% (9,10). Treatment modal-
ities include prolonged balloon
inflation, covered stent implan-
tation, pericardiocentesis for
cardiac tamponade, CABG,
nd microcoil embolization (13). Often a combination of
hese techniques is required to achieve adequate hemo-
tasis. Newer techniques such as covered stent deploy-
ent have meant that emergency CABG requirements
ave decreased (14). However, the incidence of coronary
erforation with a higher proportion of grade III perfo-
ation appears to be increasing because of higher rates of
CI in complex patient and lesion subgroups and the
idespread use of glycoprotein IIb/IIIa inhibitors
GPI) (5).
The aim of this study was to report the incidence,
redictors, treatment, and long-term outcomes of all
atients with grade III coronary perforation as a compli-
ation of PCI in the real-world setting of 2 institutions
bbreviations
nd Acronyms
ABG  coronary artery
ypass graft
PI  glycoprotein IIb/IIIa
nhibitors
VUS  intravascular
ltrasound
ACE  major adverse
ardiac event
I  myocardial infarction
CI  percutaneous
oronary intervention
TFE 
olytetrafluoroethylene
T  stent thrombosis
LR  target lesion
evascularization
VR  target vessel
evascularizationith high volumes of coronary intervention. bethods
atients. We analyzed data that had been prospectively
ollected following PCI in 2 institutions, San Raffaele
cientific Institute and EMO-GVM Centro Cuore Colum-
us Hospital, Milan, over a 16-year period from May 1993
o December 2009. All cases of grade III coronary perfora-
ion had been prospectively entered into the PCI database as
efined by the Ellis et al. (3) criteria; a retrospective analysis
f these cases was performed by 2 physicians (R.A. and A.I.)
ith information collection from the database. All original
ngiograms were reviewed by a technician (M.F.) to confirm
he occurrence of grade III perforation. A detailed review
ith clarification of all information from clinical documen-
ation and coronary angiography was then performed for all
ases by the same physicians (R.A. and A.I.) at both
nstitutions. Both physicians involved in this task had not
aken part in the procedures analyzed.
tudy deﬁnitions. Grade III coronary perforation or coro-
ary rupture was defined by the Ellis et al. (3) criteria as
xtravasation of blood through a frank perforation (1 mm)
r into an anatomic cavity chamber on coronary angiogra-
hy (3). Cardiac tamponade was defined as the presence of
or more of the following: 1) systemic hypotension (systolic
lood pressure 90 mm Hg) with evidence of pulsus
aradoxus on clinical or invasive assessment; 2) evidence of
ericardial fluid collection by angiography or by echocardi-
graphy with echocardiographic features of tamponade:
ignificant respiratory variation in transmitral Doppler ve-
ocity, dilated inferior vena cava with failure to collapse on
nspiration, or diastolic collapse of the right ventricular free
all. Periprocedural myocardial infarction (MI) was defined
s a 3-fold increase in creatine kinase-myocardial band.
uccessful treatment of grade III perforation was defined by
he absence of any angiographic evidence of contrast extrav-
sation or clinical or echocardiographic signs of cardiac
amponade. Angiographic restenosis was defined as 50%
iameter stenosis by quantitative coronary angiography
ithin a previously stented segment. Target lesion revascu-
arization (TLR) was defined as the need for any repeat
evascularization for a stenosis within the stent or within the
-mm borders adjacent to the stent. Target vessel revascu-
arization (TVR) was defined as the need for any repeat
evascularization on a treated vessel. Major adverse cardiac
vent (MACE) was defined as a combination of all cause
ortality, MI, TLR, TVR, and need for CABG. Stent
hrombosis (ST) was defined using the Academic Research
onsortium (15) definitions and cumulative ST as a com-
ination of all episodes of ST during follow-up.
rocedure. All patients were treated with aspirin and a
oading dose of a thienopyridine before the procedure.
uring the procedure, all patients were then treated with
ntravenous heparin with an initial 100-U/kg bolus followed
y further heparin as necessary to achieve a target activated
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89lotting time250 s. Ten patients (17.9%) were also treated
ith concomitant GPI therapy at the discretion of the
perator. Coronary intervention was then performed as
sual with pre-dilation, and stent implantation using stan-
ard techniques via the femoral artery as have previously
een described (16). At the time of perforation, an emer-
ency echocardiogram was performed when tamponade was
uspected; however, there were instances in which pericar-
ial drainage was performed without prior imaging if the
linical scenario demanded it. Post-operatively, all patients
eceived aspirin unless there was a specific contraindication,
nd those patients receiving an intracoronary stent received
ual antiplatelet therapy with aspirin and a thienopyridine
herapy as determined by contemporary guidelines. Follow-
ng cessation of thienopyridine therapy, all patients contin-
ed to take aspirin indefinitely.
ata collection. All patients were followed-up at regular
ntervals with clinic visits or telephone interviews. Addi-
ional data were obtained from primary care physicians,
eferring cardiologists, or relatives when necessary. All
epeat interventions and complications were prospectively
ntered into a dedicated database. Clinical follow-up was
btained in all patients, and angiographic follow-up was
btained in 56.5% of patients following successful treatment
f grade III coronary perforation.
nd points. Adverse procedural and in-hospital events were
efined as the need for cardiopulmonary resuscitation, MI,
cute ST, necessity for urgent CABG, and death. The
ong-term primary end points were defined as death from
ny cause, MI, TVR, TLR, need for CABG, and MACE at
ny time during the in-hospital stay or at follow-up. We
efined the secondary end points as the incidence of
estenosis, and ST, defined as probable, possible, or definite.
tatistical analysis. All statistical analysis was performed
sing SPSS statistical software (version 16.0, SPSS Inc.,
hicago, Illinois). Continuous variables are expressed as
ean  SD or median  interquartile range (25th percen-
ile to 75th percentile) as appropriate. Categorical variables
re expressed as counts and percentage.
Multivariable logistic regression analysis was used to
etermine independent predictors of grade III coronary
erforation, using purposeful selection of covariates. Vari-
bles associated at univariate analysis with grade III coro-
ary perforation (all with p 0.2) and those judged to be of
linical importance from previously published literature
ere eligible for inclusion into the multivariable model-
uilding process. Candidate variables included sex, circum-
ex artery lesion, mid-vessel lesion location, coronary oc-
lusions, stent implanted, directional atherectomy,
otablation, calcified lesion, bifurcation lesion, intravascular
ltrasound (IVUS) performed, diabetes mellitus, tortuous
essel, cutting balloon pre-dilation, and previous CABG.odel discrimination was measured by the C-statistic andalibration by the Hosmer-Lemeshow goodness-of-fit test
17).
esults
aseline patient and lesion demographics. From 24,465 in-
erventional procedural records, we found 56 patients who had
oronary intervention complicated by grade III coronary perfora-
ion, leading to an incidence of 0.23%. The baseline clinical
emographics of these patients are presented in Table 1. Most
atients were men, and most patients had presented with stable
ngina.
Most perforations were situated in the left anterior
escending artery, and 32.1% of these lesions were within
small vessel (2.5 mm). Ninety-six percent of lesions
ere complex with type B2 lesions in 44.6% and type C
esions in 51.8% of patients. In addition, 28.6% of lesions
ere chronic total occlusions. The baseline lesion char-
cteristics are outlined in Table 2.
rocedural characteristics. All patients were treated with
ntravenous heparin and a further 17.9% received GPI
uring the procedure as either a bolus dose or infusion.
ultivessel PCI was performed in 42.9%. Most patients
eceived an intracoronary stent; directional atherectomy
as performed in 5.4%; and cutting balloon pre-dilation
as carried out in 10.7%. In addition, IVUS was used to
uide PCI in 50.0% of cases. The baseline procedural
haracteristics are shown in Table 3.
The device causing perforation was an intracoronary balloon in
0.0% (n  28) of patients with a compliant balloon used in
3.6% (n 15) and a noncompliant balloon used in 46.4% (n
3). Perforation occurred during pre-dilation before stent implan-
Table 1. Baseline Clinical Characteristics (n  56)
Age, yrs 66.5 12.1
Male sex 44 (78.6)
Ejection fraction 55.8 9.1
Prior myocardial infarction 25 (44.6)
Prior PCI 22 (39.3)
Prior CABG 6 (10.7)
Unstable angina (CCS IV) 4 (7.1)
Stable angina (CCS I–III) 46 (82.2)
Silent ischemia (CCS 0) 6 (10.9)
Multivessel disease 42 (76.4)
Renal impairment (plasma creatinine 1.4 mg/dl) 4 (7.1)
Cardiovascular risk factors
Family history of coronary artery disease 22 (39.3)
Hypertension 35 (62.5)
Hypercholesterolemia 38 (67.9)
Current smoker 5 (8.9)
Diabetes mellitus 8 (14.3)
Data presented as percentages and absolute numbers or mean SD.
CABG coronary artery bypass graft; CCS Canadian Cardiovascular Society; PCI percuta-neous coronary intervention.
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90ation in 39.3% (n 11) and during post-dilation following stent
eployment in 60.7% (n  17) of patients. The mean balloon
rtery ratio was 1.3 0.2 mm in the compliant balloon group and
.3  0.3 mm in the noncompliant balloon group. The balloon
elivering an intracoronary stent caused vessel perforation in
7.8% (n 10) of patients, whereas this complication was caused
y an intracoronary guidewire in 17.9% (n  10) with most of
hese wires being non-hydrophilic (n  8, 80%).
anagement and procedural outcomes. Following grade
II coronary perforation, pericardiocentesis for cardiac
amponade was performed in 28.6% (n  16) and an
ntra-aortic balloon pump was implanted as an emergency
n 19.6% (n  11) of patients. The overall success rate
ollowing treatment of perforation was 87.7% (n  50).
he perforation was treated with prolonged balloon
nflation in 58.9% (n  33); however, this technique was
nly successful in 54.5% (n  18) of those treated.
overed stent implantation was performed to treat the
rade III coronary perforation in 46.4% (n  26) and had
higher success rate with hemostasis achieved in 84.6%
n  22) of patients (Fig. 1). Of the cases treated with
overed stent implantation, 96.1% (n  25) had polytet-
afluoroethylene (PTFE) stents implanted, and in 1 case,
custom-made saphenous vein graft– covered stent was
mplanted in the era before the availability of covered
tents. From 25 PTFE stents implanted, 22 were Jostent
oronary graft stent (Abbott Vascular Laboratories, Red-
Table 2. Lesion Characteristics (n  56)
Vessel
Left anterior descending 25 (44.6)
Circumﬂex 7 (12.5)
Right coronary artery 13 (23.2)
Intermediate 1 (1.8)
First diagonal 3 (5.4)
Second diagonal 1 (1.8)
Obtuse marginal 3 (5.4)
Septal 1 (1.8)
Saphenous vein graft 2 (3.6)
Lesion location
Ostial 4 (7.1)
Proximal 22 (39.2)
Mid 26 (46.4)
Distal 4 (7.1)
Lesion and vessel morphology
Type A 0
Type B1 2 (3.6)
Type B2 24 (44.6)
Type C 29 (51.8)
Chronic total occlusion 16 (28.6)
Signiﬁcant calciﬁcation 13 (23.2)
Small vessel 2.5 mm 18 (32.1)
Data presented as percentages and absolute numbers or mean SD.ood City, California) and 3 were Direct-Stent stentrafts (InSitu Technologies Inc., Minneapolis, Minne-
ota) with 3-, 3.5-, and 4-mm diameters and 12-, 16-,
nd 19-mm lengths. Implantation of a standard stent was
erformed in 17.9% (n  10) of cases but was only
uccessful in treating the perforation in a minority of
atients (n  3, 30.0%). Coil embolization was per-
ormed in 1 patient and was successful in sealing the
erforation. An emergency CABG was performed in
6.0% (n  9) but was only successful in sealing the
upture in 44.4% (n  4). Multiple methods of treatment
ere required in an attempt to achieve hemostasis in
9.3% (n  22). During the procedure, cardiopulmonary
esuscitation was required in 19.6% (n  11), and the
verall intraprocedural mortality rate was 3.6% (n  2).
he characteristics of grade III coronary perforation and
reatment are outlined in Table 4.
redictors of grade III coronary perforation. Multivariable
ogistic regression was used to assess predictors of grade III
oronary perforation. The c-statistic for the propensity score
odel was 0.78, indicating excellent discrimination. The
osmer-Lemeshow goodness-of-fit test p value was 0.99,
onfirming good calibration and fit of the multivariable
odel that estimated the propensity score. The significant
redictors of perforation are presented in Table 5.
n-hospital outcomes. During the in-hospital period, 1
atient had an acute ST following covered stent implan-
ation and 2 patients required urgent CABG and surgical
epair of perforation following presentation pericardial
ffusion 2 to 3 days following the procedure. The
ombined procedural and in-hospital MI rate was 42.9%
n  24). In addition, 14.8% (n  8) died during the
ndex hospitalization period leading to a total mortality
ate of 17.9% (n  10) and a combined procedural and
n-hospital MACE rate of 55.4% (n  31).
Table 3. Baseline Procedural Characteristics (n  56)
Glycoprotein IIb/IIIa inhibitors 10 (17.9)
Unfractionated heparin 56 (100)
Multivessel stenting 24 (42.9)
Devices used during procedure
Compliant balloon 26 (46.4)
Noncompliant balloon 21 (37.5)
Intracoronary stent 44 (78.6)
Cutting balloon 6 (10.7)
Directional atherectomy 3 (5.4)
Rotablation 9 (16.1)
Intravascular ultrasound 28 (50.0)
Type of guidewire used
Standard (nonhydrophilic) 38 (67.9)
Light support (nonhydrophilic) 7 (12.5)
Intermediate support (nonhydrophilic) 16 (28.5)
High support (nonhydrophilic) 17 (30.3)
Hydrophilic 12 (21.4)Data presented as percentages and absolute numbers or mean SD.
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91A subgroup analysis of the 10 patients who had GPI and
eparin therapy is summarized in Table 6. In this group the
roportion of patients who needed multiple treatment
ethods was higher than the overall group at 50.0% (n 
), and overall rate of successful treatment of perforation
as 80.0% (n  8). In addition, the procedural and
n-hospital MACE rate was 90.0% (n  9) with 1 death
uring the procedure and 1 death during the in-hospital
eriod.
ollow-up clinical outcomes. Clinical follow-up was achieved
n all patients with median follow-up of 38.1 months (7.6 to
22.8). Most patients (n  44, 95.7%) were asymptomatic at
ollow-up with symptoms of stable angina in the remainder
n 2, 4.3%). The in-stent restenosis rate was 38.5% (n 10)
Figure 1. Example of Grade III Coronary Perforation Before and After Treat
(A) Grade III coronary perforation following percutaneous coronary interventio
achieved following covered stent implantation.
Table 4. Characteristics of Grade III Coronary Perforation (n  56)
Device causing rupture
Compliant balloon 15 (26.8)
Mean balloon artery ratio 1.3 0.2
Noncompliant balloon 13 (23.2)
Mean balloon artery ratio 1.3 0.3
Stent delivery system 10 (17.8)
Cutting balloon 4 (7.1)
Directional atherectomy 2 (3.6)
Rotablation 2 (3.6)
Hydrophilic wire 2 (3.6)
Nonhydrophilic wire 8 (14.3)
Action following rupture
Pericardiocentesis 16 (28.6)
Emergency intra-aortic balloon pump 11 (19.6)
Heparin reversal 24 (42.9)Data presented as percentages and absolute numbers or mean SD.ith 60.0% (n 6) of these being occlusive. The MACE rate
t follow-up was 41.3% (n 19), which was composed of MI
n 4.3% (n 2), all-cause mortality in 15.2% (n 7), need for
ABG in 4.3% (n 2), TLR in 13.0% (n 6), and TVR in
9.6% (n  9). Definite ST occurred in 4 patients (8.6%), all
f whom had covered stent implantation to treat grade III
erforation. One of these patients experienced recurrent epi-
odes of subacute ST following PTFE stent implantation at 9
1, and 30 days after the index procedure despite maximal
ntiplatelet and anticoagulant therapy; on each of these occa-
ions, he had repeat angiography and repeat PCI and went on
o have CABG but subsequently died of cardiogenic shock.
ne patient experienced subacute ST on dual antiplatelet
herapy 7 days following the index PCI procedure with
mplantation of a PTFE stent; he subsequently had repeat PCI
ith drug-eluting stent implantation. One patient presented
ith late ST 3 months following PTFE implantation at the
ndex procedure while taking dual antiplatelet therapy; he was
reated with conventional balloon angioplasty and made a good
ecovery. One patient presented with late ST 2 months after
TFE stent implantation while taking dual antiplatelet therapy
nd was managed conservatively. Long-term clinical and an-
Table 5. Logistic Regression Analysis for Predictors of Grade III
Coronary Perforation
OR 95% CI for OR p Value
Type B2/C lesions 3.75 1.47–9.60 0.006
Coronary occlusion 1.91 1.02–3.60 0.045
Rotablation performed 3.47 1.59–7.58 0.002
Intravascular ultrasound–guided procedure 5.36 3.10–9.25 0.001
aphenous vein graft. (B) Successful treatment of coronary perforationment
n to sCI confidence interval; OR odds ratio.
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92iographic outcomes during the follow-up period are presented
n Table 7.
iscussion
he main findings of this paper are: 1) the incidence of grade
II coronary perforation was extremely rare; 2) predictors of
rade III coronary perforation were complex coronary lesions,
oronary occlusions, and the use of rotablation and IVUS;
) multiple methods of treatment are available, but prolonged
alloon inflation and covered stent implantation were success-
ul in a reasonable proportion of cases; 4) despite improve-
ents in the treatment of grade III coronary perforation, rates
f MI and mortality remained high; 5) the occurrence of grade
II coronary perforation following administration of GPI was
ssociated with increased procedural and in-hospital MACE
ates; and 6) from 1993 to 2009, the incidence of grade III
oronary perforation remained relatively unchanged, but there
as an improvement in procedural and in-hospital MACE
ates (Fig. 2).
Grade III coronary perforation is a feared and dramatic
omplication of PCI with poor immediate outcomes and
ery high mortality rates. It remains a rare event with an
ncidence of 0.23% in our centers in the context of high
olumes of PCI. Over time, the number of cases of grade III
Table 6. Treatment and Procedural Outcomes Following Grade III Coronary
Lesions Overall Group
Treatment of rupture n  56
Prolonged balloon inﬂation 33 (58.9)
Successful 18 (54.5)
Covered stent implantation 26 (46.4)
Successful 22 (84.6)
Standard stent implantation 10 (17.9)
Successful 3 (30.0)
Coil embolization 1 (1.8)
Successful 1 (100)
CABG and surgical repair of perforation 9 (16.0)
Successful 4 (44.4)
Multiple treatment methods used 22 (39.3)
Overall successful treatment of rupture 50 (87.7)
Procedural complications n  56
Cardiopulmonary resuscitation 11 (19.6)
Death 2 (3.6)
In-hospital complications n  54
Acute stent thrombosis 1 (1.9)
Necessity for CABG 2 (3.7)
Death 8 (14.8)
Combined procedural and in-hospital events n  56
Myocardial infarction 24 (42.9)
Major adverse cardiac event 31 (55.4)
Data presented as percentages and absolute numbers or mean SD.
GPI glycoprotein IIb/IIIa inhibitors; other abbreviations as in Table 1.oronary perforation has remained constant, as a likely peflection of the increased complexity of procedures. How-
ver, even though the combined procedural and in-hospital
ACE rate is high at 55%, there has been some improve-
ent over time since the introduction of techniques such as
overed stent implantation. Despite the available treat-
ents, these methods are often unsuccessful in achieving
emostasis and multiple modalities are frequently required.
otably, these outcomes were achieved in centers with
xperienced operators, and success rates may be even less
avorable in the hands of less experienced operators. From
ur study, the commonest cause of grade III coronary
erforation was inflation of an intracoronary balloon, with
o change in the incidence based on the balloon compli-
nce. Grade III coronary perforation was caused by rotab-
ation, directional atherectomy, and cutting balloon infla-
ion in only a small number of cases; however, this figure
ay be influenced by the low rates of use of these adjunctive
echniques in our interventional practice. Interestingly, in
ases of perforation due to an intracoronary guidewire, the
ire was nonhydrophilic in the majority, in contrast to
revious reports (18). However, as the total numbers of
ases were relatively small this finding may be a reflection of
he fact that our first-line choice of guidewire is uncoated.
n assessment of the predictors of grade III coronary
ration
Patients Not Treated With GPI Patients Treated With GPI
n  46 n  10
27 (58.7) 6 (60.0)
16 (59.3) 2 (33.3)
20 (43.4) 6 (60.0)
17 (85.0) 5 (83.3)
10 (21.7) 0
3 (30.0) 0
1 (2.2) 0
1 (100) 0
6 (13.0) 3 (30.0)
3 (50.0) 1 (33.3)
17 (37.0) 5 (50.0)
42 (91.3) 8 (80.0)
n  46 n  10
4 (8.7) 3 (30.0)
1 (2.2) 1 (10.0)
n  45 n  9
1 (2.2) 0
1 (2.2) 1 (11.1)
7 (15.5) 1 (11.1)
n  46 n  10
17 (37.0) 7 (70.0)
22 (47.8) 9 (90.0)Perfoerforation showed that this adverse event was associated
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93ith complex coronary lesions (type B2 or C lesions),
oronary occlusions, and the use of rotablation or IVUS
uring the procedure. In addition, the incidence of definite
T was relatively high at 8.6%; all of these cases were
ssociated with covered PTFE stent implantation and
llustrates the thrombogenic nature of these stents, in
ombination with the increased risk of ST conferred by
oronary perforation. This finding highlights the need for
ess thrombogenic stents for the treatment of coronary
erforation.
Table 7. Long-Term Outcome During the Follow-Up Period
Follow-up 46
Months 38.1 (7.6–122.8)
Months of dual antiplatelet therapy 1.0 (0–6.0)
Angiographic follow-up obtained 26 (56.5)
Angina CCS class
Unstable angina (CCS IV) 0
Stable angina (CCS I–III) 2 (4.3)
Asymptomatic (CCS 0) 44 (95.7)
Restenosis 10 (38.4)
Death following discharge 7 (15.2)
Cardiac death 3 (6.5)
Myocardial infarction 2 (4.3)
Need for CABG 2 (4.3)
Target lesion revascularization 6 (13.0)
Target vessel revascularization 9 (19.6)
Stent thrombosis 4 (8.6)
Major adverse cardiac event 19 (41.3)
Data presented as percentages and absolute numbers, mean  SD, or median (interquartile
range).
Abbreviations as in Table 1.
Figure 2. Incidence, Treatment, and Outcomes of Grade III Perforation From
Graph showing number of cases of grade III coronary perforation, number of c
adverse event rates over each 2- to 3-year period from 1993 to 2009. Figures
procedures performed within each period. MACE  major adverse cardiac event.Previous studies have focused on an analysis of a com-
ined group of all 3 grades of coronary perforation and have
uggested that this complication is more common during
CI to type C lesions (2,9); this was confirmed by our study,
ith a predominance of complex type B2 or C lesions. It has
lso been suggested that coronary perforation is more
revalent during coronary intervention in females (2); how-
ver, sex was not a predictor of grade III coronary perfora-
ion in our study. Shimony et al. (9) reported that the
ncidence of coronary perforation may be associated with
ntervention to the right coronary artery and attributed this
o the tortuous course of this vessel; however, in our study,
natomic lesion location was not a predictor of perforation.
his may be a result of differences between the character-
stics of vessels with grade III coronary perforation com-
ared with those with less severe forms of perforation. Both
he use of rotablation and IVUS were predictors or grade III
oronary perforation in our study, reflecting the association
etween this adverse event and a more complex lesion
ubset. Notably, the use of IVUS was shown to be associated
ith coronary perforation in a previous study by our group
nd is likely to be a reflection of the fact that IVUS is more
ikely to be used in complex lesions or those in which PCI
s complicated, for example, by balloon underexpansion
uring pre-dilation (19). Regarding treatment of grade III
oronary perforation, it appears that we still do not have an
deal modality to treat this dramatic complication despite
eported promising outcomes following covered stent im-
lantation and microcoil embolization (20,21). Even with
ewer treatment methods, multiple treatment modalities
ere still required in 39% and although successful hemo-
tasis was achieved in 88%, our combined procedural and
3 to 2009
f successfully treated, and combined in-hospital and procedural major
ite boxes represent total number of percutaneous coronary intervention199
ases o
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94n-hospital mortality rate remained high at 18%, in line with
revious reported mortality rates of 7% to 44% in grade III
erforation (9–12). Furthermore, the rates of in-hospital
I remained very high at 43%. Based on our experience of
he treatment of grade III coronary perforation, we present
proposed treatment flowchart that can be considered in
he instance of this adverse event (Fig. 3).
This study also showed that grade III coronary perfo-
ation in conjunction with GPI administration was asso-
iated with an even greater risk of adverse events. The
ombined procedural and in-hospital MACE rate in this
roup was higher than that of the overall group at 90%.
n addition, multiple treatment modalities were required
n 50% in an attempt to achieve hemostasis with success-
ul treatment of the rupture in 80%. Previous studies have
lso suggested that the use of GPI may be associated with
orse short-term outcomes in patients with coronary
erforation and that these agents should be used with
aution in high-risk procedures (5).
tudy limitations. There are some limitations of this study:
) it was a retrospective study; 2) the population size was
Figure 3. Flowchart for the Treatment of Grade III Coronary Perforation Ba
An algorithm for the management of grade III coronary perforation based on
CABG  coronary artery bypass graft; GPIIbIIIa  glycoprotein IIb/IIIa inhibitors; IABPelatively small; 3) angiographic follow-up was not per-
ormed in all patients; and 4) it was a descriptive study with
o control group, but an attempt to match according to
atient or lesion characteristics to such a specific population
ay be inaccurate and misleading. Previous reports of
oronary perforation during PCI have also assessed rela-
ively small numbers of patients, as it is a rare event.
onclusions
ortunately, grade III coronary perforation remains a rare
omplication of coronary intervention, with an incidence
hat may be rising due to increased complexity of cases in
urrent practice and widespread use of GPI. Predictors of
rade II coronary perforation are complex coronary lesions,
oronary occlusions, and the use of rotablation and IVUS.
n interventional cardiologist must be prepared for this
atrogenic event; all teams should be equipped with the
ecessary skills and technology required for treatment and
hould be prepared to react quickly and efficiently in the
vent of perforation. Despite treatment measures, this
Our Experience
perience of the most successful and appropriate methods of treatment.sed on
our ex
 intra-aortic balloon pump.
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95omplication is still associated with poor adverse outcomes
nd there remains a need for improved technology to treat
his dreaded complication.
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